Telesis Bio, Inc. is a biotechnology company focused on advancing genetic engineering and synthetic biology technologies
The company specializes in developing innovative solutions for DNA and RNA synthesis, enabling researchers and companies to streamline their workflows in genomics, therapeutics, and bioengineering. Telesis Bio aims to enhance the precision and efficiency of custom DNA and RNA production, supporting a wide range of applications from basic research to the development of novel therapies. Their cutting-edge platforms and solutions are designed to empower scientists and accelerate discoveries in the life sciences sector.
SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQTBIO) (“Telesis” or the “Company”), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, flexible, and rapid automated synthesis technology in their own lab, announced today that it has notified the Nasdaq Stock Market LLC (“Nasdaq”) of its decision to delist the Company’s shares of common stock, par value $0.001 per share (the “Common Stock”) and deregister the Common Stock under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).
SAN DIEGO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQTBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, flexible, and rapid automated synthesis technology in their own lab, today announced financial results for the second quarter and first half of 2024.
